Your browser doesn't support javascript.
loading
Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): A report from the European MDS registry.
Madry, Krzysztof; Lis, Karol; Fenaux, Pierre; Bowen, David; Symeonidis, Argiris; Mittelman, Moshe; Stauder, Reinhard; Cermák, Jaroslav; Sanz, Guillermo; Hellström-Lindberg, Eva; Langemeijer, Saskia; Malcovati, Luca; Germing, Ulrich; Holm, Mette Skov; Guerci-Bresler, Agnes; Culligan, Dominic; Sanhes, Laurence; Kotsianidis, Ioannis; van Marrewijk, Corine; Crouch, Simon; de Witte, Theo; Smith, Alex.
Afiliação
  • Madry K; Department of Haematology, Transplantation and Internal Medicine, Warszawa Medical University, Warsaw, Poland.
  • Lis K; Department of Haematology, Transplantation and Internal Medicine, Warszawa Medical University, Warsaw, Poland.
  • Fenaux P; Service d'Hématologie, Hôpital Saint-Louis, Assistance Publique des Hôpitaux de Paris (AP-HP) and Université Paris 7, Paris, France.
  • Bowen D; St. James's Institute of Oncology, Leeds Teaching Hospitals, Leeds, UK.
  • Symeonidis A; Department of Medicine, Division of Hematology, University of Patras Medical School, Patras, Greece.
  • Mittelman M; Department of Medicine A, Tel Aviv Sourasky (Ichilov) Medical Center and Sackler Medical Faculty, Tel Aviv University, Tel Aviv, Israel.
  • Stauder R; Department of Internal Medicine V (Haematology and Oncology), Innsbruck Medical University, Innsbruck, Austria.
  • Cermák J; Department of Clinical Hematology, Institute of Hematology & Blood Transfusion, Praha, Czech Republic.
  • Sanz G; Department of Haematology, Hospital Universitario y Politécnico La Fe & Scientific Director IIS La Fe, Madrid, Spain.
  • Hellström-Lindberg E; Department of Medicine, Division of Hematology, Karolinska Institutet, Stockholm, Sweden.
  • Langemeijer S; Department of Hematology, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Malcovati L; Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.
  • Germing U; Department of Haematology, Oncology and Clinical Immunology, Universitätsklinik Düsseldorf, Düsseldorf, Germany.
  • Holm MS; Department of Haematology, Aarhus University Hospital, Aarhus, Denmark.
  • Guerci-Bresler A; Service d'Hématologie, Centre Hospitalier Universtaire Brabois Vandoeuvre, Nancy, France.
  • Culligan D; Department of Haematology, Aberdeen Royal Infirmary, Aberdeen, UK.
  • Sanhes L; Service d'Hématologie, Centre Hospitalier de Perpignan, Perpignan, France.
  • Kotsianidis I; Department of Hematology, Democritus University of Thrace Medical School, University Hospital of Alexandroupolis, Alexandroupolis, Greece.
  • van Marrewijk C; Department of Hematology, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Crouch S; Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, UK.
  • de Witte T; Department of Tumor Immunology - Nijmegen Center for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Smith A; Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, UK.
Br J Haematol ; 200(4): 451-461, 2023 02.
Article em En | MEDLINE | ID: mdl-36335984
Information on causes of death (CoDs) and the impact of myelodysplastic syndromes (MDS) on survival in patients with lower-risk MDS (LR-MDS) is limited. A better understanding of the relationship between disease characteristics, clinical interventions and CoDs may improve outcomes of patients with LR-MDS. We prospectively collected data on patients with LR-MDS in the European MDS registry from 2008 to 2019. Clinical, laboratory and CoDs data were obtained. To examine MDS-specific survival, relative survival (RS) was estimated using national life tables. Of 2396 evaluated subjects, 900 died (median overall survival [OS]: 4.7 years; median follow-up: 3.5 years). The most common CoDs were acute myeloid leukaemia/MDS (20.1%), infection (17.8%) and cardiovascular disease (CVD; 9.8%). Patients with isolated del(5q) and with red cell transfusion needed during the disease course, had a higher risk of fatal CVD. The 5-year OS was 47.3% and the 5-year RS was 59.6%, indicating that most patients died due to their underlying MDS. Older patients (aged >80 years) and the lowest-risk patients were more likely to die from competing causes. This study shows that MDS and its related complications play crucial role in the outcome of patients with LR-MDS.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Síndromes Mielodisplásicas / Doenças Cardiovasculares / Leucemia Mieloide Aguda Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Síndromes Mielodisplásicas / Doenças Cardiovasculares / Leucemia Mieloide Aguda Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article